Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Boston Scientific’s FARAPULSE system is showing some serious promise in zapping away persistent atrial fibrillation, ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...